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Abstract
Background: More than 200 clinical trials have been performed using dendritic cells (DC) as cellular adjuvants in cancer. Yet
the key question whether there is a link between immune and clinical response remains unanswered. Prostate and renal cell
cancer (RCC) have been extensively studied for DC-based immunotherapeutic interventions and were therefore chosen to
address the above question by means of a systematic review and meta-analysis.
Methodology/Principal Findings: Data was obtained after a systematic literature search from clinical trials that enrolled at
least 6 patients. Individual patient data meta-analysis was performed by means of conditional logistic regression grouped
by study. Twenty nine trials involving a total of 906 patients were identified in prostate cancer (17) and RCC (12). Objective
response rates were 7.7% in prostate cancer and 12.7% in RCC. The combined percentages of objective responses and
stable diseases (SD) amounted to a clinical benefit rate (CBR) of 54% in prostate cancer and 48% in RCC. Meta-analysis of
individual patient data (n=403) revealed the cellular immune response to have a significant influence on CBR, both in
prostate cancer (OR 10.6, 95% CI 2.5–44.1) and in RCC (OR 8.4, 95% CI 1.3–53.0). Furthermore, DC dose was found to have a
significant influence on CBR in both entities. Finally, for the larger cohort of prostate cancer patients, an influence of DC
maturity and DC subtype (density enriched versus monocyte derived DC) as well as access to draining lymph nodes on
clinical outcome could be demonstrated.
Conclusions/Significance: As a ‘proof of principle’ a statistically significant effect of DC-mediated cellular immune response
and of DC dose on CBR could be demonstrated. Further findings concerning vaccine composition, quality control, and the
effect of DC maturation status are relevant for the immunological development of DC-based vaccines.
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Introduction
For more than a century it has been hypothesized that the
immune system can be redirected to target malignant cells and thus
cure cancer [1,2]. This concept is based on the notion of cancer
immunosurveillance [3]. In accordance to this concept it was shown
that in patients with colon cancer the density of infiltrating, antigen-
experienced T cells correlated better with clinical outcome than
classical histopathological staging [4]. Furthermore, it could be
demonstrated that people with a high degree of natural cytotoxicity
had a lower risk to develop cancer [5].
Dendritic cells (DC) [6] play a crucial role in the induction of
antigen-specific T-cell responses and are therefore the most
frequently used cellular adjuvant in clinical trials. However, the
heterogeneity of vaccination algorithms, non-standardized cellular
products and the lack of established criteria for clinical and
immune responses has made it impossible to draw valid
conclusions from single clinical trials [7–10]. The key questions
about whether induction of immunity is linked to clinical response
and whether a dose-response relationship exists remain unan-
swered. Prostate and renal cell cancer (RCC) are regularly
infiltrated by antigen-specific immune cells and are considered
susceptible to immunotherapy [11–13]. DC vaccination has been
extensively studied in these cancers [14–18]. Additionally, the
clinical response criteria used for these tumor entities are
complementary: Conventional RECIST/WHO criteria in RCC
and combination of radiographic criteria with biochemical
markers in prostate cancer. For these reasons, they were identified
as an ideal model for a systematic review of DC-based tumor
vaccines. The aim of this study was to analyze the studies identified
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18801in the literature search concerning vaccination strategies, quality
control, and induction of immune and clinical response. Further-
more, using individual-patient data the hypothesis was tested
whether induction of immunity indeed leads to disease control.
Additionally, immunologic properties with potential influence on
vaccination success (e.g. maturation status, access to draining
lymph nodes) were analyzed.
Methods
Literature search, inclusion and exclusion criteria
A highly sensitive search string for Medline-Ovid was developed
in which keywords related to ‘cancer’, ‘dendritic cells’, and ‘clinical
trial’ were combined (Text S1). The Medline database search
covered the period from January 1987 to September 2008, and
was recently up-dated covering the period until December 2010.
The search was performed in accordance to the PRISMA
statement [19] which is focused on meta-analysis of randomized
trials, but can be used as a general basis for systematic reviews.
Clinical trials using DC in prostate and RCC, that enrolled at
least 6 patients, published between January 2000 and December
2010, and in English language were included. Studies in which
different tumor entities were treated, follow-up studies, and trials
using allogeneic DC were excluded.
Study selection and data extraction
Two reviewers (NKG and SM) independently screened the
articles identified in the literature search. Disagreements between
the reviewers (about 15% of the cases) were resolved by a
consensus involving two other reviewers (AD, MBB). Data were
collected both at trial and individual patient level in an Access
database for: DC subtype, phenotype and purity, antigen delivery,
route of vaccination, dose (number of DC per vaccination
* number of vaccinations), adjuvants given, toxicity, immune
monitoring, and clinical response. Additionally, the following
individual patient information was recorded: age, gender, staging,
pretreatment, and concomitant therapy. Although information
given on phenotype regarding the maturation status of DC was
documented, it was the maturation status indicated by the authors
that was assumed for the meta-analysis. A cellular or humoral
immune response was considered positive when at least one
method led to a positive result for the specific antigen, if had not
already been detected before vaccination. For clinical outcome,
complete response (CR), partial response (PR), mixed response
(MR), stable disease (SD), and progressive disease (PD) were
documented. The term clinical benefit rate (CBR) was used
representing the rate of patients who were either in CR, PR, MR,
or SD [20].
Statistical methods
Descriptive analyses were performed both at study data level
and at individual patient data level. Prostate and RCC trials were
analyzed separately. Available individual patient data was used for
meta-analysis. Variables were dichotomized: 1) DC subtype:
mature monocyte-derived DC (mat-moDC) vs. immature mono-
cyte-derived DC (imm-moDC); 2) route: intravenous (i.v.) vs.
intradermal (i.d.)/intranodal (i.n.)/intralymphatic (i.l)/subcutane-
ous (s.c.); 3) total DC dose for prostate cancer: $86.4610
6
(median) vs. ,86.4610
6; 4) total DC dose for RCC: $38.7610
6
(median) vs. ,38.7610
6; 5) age $65 vs. ,65; 6) clinical response:
PD vs. CR, PR, MR, SD; 7) cellular and 8) humoral immune
response: positive vs. negative.
Influences on clinical outcome of cellular immune response,
humoral immune response, total DC dose, and age were assessed
by means of conditional logistic regression grouped by study, thus
adjusting varying vaccination protocols or response criteria. Odds
ratios (OR) with 95% confidence intervals were calculated.
Additionally, the influence of the continuous variable ‘‘logarithm
of total DC dose (logdose)’’ on clinical outcome was assessed.
Forest plots were supplemented with the overall Mantel-Haenszel
estimate (fixed effect).
Data on variables constant within trials, i.e. DC subtype and
route of vaccination, were pooled and analyzed by Pearson’s chi-
square test (unstratified). P-values smaller than 0.05 were
considered to indicate statistical significance though no correction
for multiple testing was applied. Statistical analyses were
performed in IBM SPSS Statistics 19.0 (IBM SPSS Statistics
Inc., Chicago, IL), Stata 11.1 (StataCorp, College Station, TX) or
Comprehensive Meta Analysis 2.2 (Biostat, Englewood, NJ).
Results
Identification of studies
Of 268 articles identified as reports about clinical trials, 41 were
conducted in patients with prostate cancer or RCC. Among these, 12
were excluded for the following reasons: follow-up studies (4) [21–
24]; use of allogeneic DC (1) [25]; inclusion of two tumor entities
(1) [26]; ,6 patients (3) [27–29]; not written in English (1) [30];
lack of information about clinical outcome (1) [31]; and follow-up
reporting of the same study (1) [32,33]. One study included both
prostate and RCC patients; however, only prostate cancer patients
were included because the number of patients with RCC was only
five [34]. Figure 1 displays the search process.
Twenty nine studies in prostate (17) and RCC (12) met all
inclusion criteria and were subject of this meta-analysis [33–61]. In
total, the studies included 906 patients (prostate cancer 720, RCC
186). Apart from three randomized phase III studies in prostate
cancer [33,40,42], all trials were phase I/II clinical studies. The
histological RCC subtype was specified in 10 of 12 studies and was
either clear cell in all patients [51,52,54,59,61] or clear cell in the
vast majority of patients with few exceptions (in all studies ,15%:
papillary, clear cell/sarcomatoid or chromophilic) [50,53,55,57,
58]. The median patient number within the phase I/II studies was
14 for prostate cancer (range 6–31) and 12 for RCC (range 8–35)
(Table 1).
Patient characteristics
In prostate cancer, 662 patients had metastatic disease, 51
biochemical relapse, and 7 local recurrence. All RCC patients
had metastatic disease (Table S1).
87% (458/526 patients with data available) of prostate cancer
patients had prior surgery or radiotherapy, 17% (109/646) prior
chemotherapy, and 96% (632/660) prior hormone therapy or
castration. In one prostate cancer trial all patients received IFN-c
simultaneously [41].
92% (142/154 patients with data available) of RCC patients had
prior surgery or radiotherapy, 17% (24/143) prior chemotherapy
and 36% (54/151) prior immunotherapy. In 36% (67/182) of RCC
patients systemic IL-2 [50,57,60] or IL2/IFN-a [58] was
simultaneously applied to the DC vaccine. In one study, IL2 was
given immediately after the last vaccination [61]. In two studies, 3
and 6 patients, respectively, received IL-2, IL-2/IFN-c or IL2/
IFN-c/5-FU after the end of the vaccination period [56,59].
Vaccines
Prostate Cancer. Imm-moDC were used in 5 trials (90
patients) [34,35,39,44,45], whereas mat-moDC were used in 6
trials (77 patients) [38,41,43,47–49]. In 3 phase I/II studies (65
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[33,40,42] density-enriched DC were used. Numerous strategies
for antigen delivery were employed (Table 1): Peptide pulsing was
preferred in 6 studies [38,41,44,45,48,49]; loading with whole
protein in 7 studies [33,35–37,40,42,46]; loading with tumor
lysates in one study [34]; and RNA transfection or coincubation in
3 studies [39,43,47]. In 11 studies (87% of all prostate cancer
patients), vaccination was intravenously applied or an intravenous
and a non-intravenous route (i.d., s.c., i.l., i.n.) were combined. In
6 studies (13% of all patients) a non-intravenous route was
preferred. Details are compiled in Table 1.
Cell numbers applied per vaccination and numbers of
vaccination are given in Table S2.
RCC. Imm-moDC were used in 3 studies (34 patients)
[53,57,59], whereas mat-moDC in 9 studies (152 patients) [50–
52,54–56,58,60,61]. Peptide pulsing was chosen in two studies
[51,61]; loading with tumor lysates in 6 studies [53–58]; RNA
coincubation in two studies [52,59]; and cell fusion with
autologous tumor cells in another study [60]. In one study DC
were either loaded with peptides or tumor lysate [50]. In 10 studies
a non-intravenous route was chosen (84% of all RCC patients),
whereas in two studies (16% of patients) an intravenous or a
combined vaccination was preferred (Table 1).
Comparison of vaccines between prostate cancer and
RCC trials. In prostate cancer trials an intravenous route or a
combination of different routes was the strategy most frequently
preferred, whereas a non-intravenous route was chosen in the
majority of RCC trials. In regard to the total patient number most
prostate cancer patients received density-enriched DC, which was
due to the large randomized trials, whereas most RCC patients
received mat-moDC. In prostate cancer trials, pulsing with defined
peptides or proteins was the preferred antigen delivery strategy,
whereas in RCC it was pulsing with tumor cell lysates.
In regard to individual patient data available for the meta-
analysis compared to the study data level described above, it is
important to mention that for prostate cancer the percentages of
patients receiving mat-moDC, imm-moDC, and density-enriched
DC were more evenly distributed with 33%, 39%, and 28%,
respectively. The ratio of intravenous - non-intravenous route was
also more evenly distributed: 52% vs. 48% (compare to Table 1
and Table S5). In contrast, for RCC individual-patient data
available, the uneven distribution regarding the route of
vaccination and the DC maturation status was the same compared
to the study data level described above.
Quality controls
To determine quality control of the DC-based vaccines, criteria
proposed by Figdor and colleagues were followed concerning
phenotype and purity [62]. The authors suggested six surface
antigens for mat-moDC to be documented (CD83, CD80, CD86,
MHC-I, MHC-II, CCR7) and 7 for imm-moDC (CD14, CD83,
CD80, CD86, MHC-I, MHC-II, CCR5). No trial using moDC
reported all antigens proposed. Nevertheless, in prostate cancer two
studies reported 5 of 6 and 6 of 7; in RCC four studies reported 5 of 6
and 6 of 7 proposed antigens for mat-moDC and imm-moDC,
respectively [39,49–51,55,59]. On the other hand, two prostate cancer
studies and three RCC studies failed to report the phenotype
[34,44,53,56,60]. The majority of the studies provided information
forthefollowingsurrogatemarkers:CD14 (prostatecancer8/17 studies,
RCC 7/12 studies), HLA-DR (prostatecancer 11/17, RCC 7/12), CD86
Figure 1. Flow diagram showing record identification, record screening, full text article eligibility and study inclusion process.
doi:10.1371/journal.pone.0018801.g001
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Prostate cancer
Reference Patients DC
Antigen
(+ helper antigen)
Antigen
processing Adjuvant Route
Humoral
immune
response*
Cellular
immune
response*
Clinical
response
+
Barrou,
2004 [35]
24 imm-moDC rPSA protein i.v.+s.c.+i.d. 0/24 11/24 11/24 SD
Burch,
2000 [36]
13 density
enriched
PA2024
1 protein PA2024 s.c. i.v. 11/11 9/9 3/13 PR,
9/13 SD
Fong,
2001 [37]
21 density
enriched
muPAP protein i.v. or i.d.
or i.l.
10/21 21/21 6/21 SD
Fuessel,
2006 [38]
8 mat-moDC PSA3, PSMA1, prostein,
survivin, Trp-p8
peptide i.v. + i.d. n.d. 4/8 1/8 PR, 3/8 SD
Heiser, 2002 [39] 13 imm-moDC PSA mRNA i.v. + i.d. 0/13 10/10 n.d.
Higano,
2009 [40]
{
65
{ density
enriched
PA2024
1 protein i.v. n.d. n.d. n.d.
Hildenbrand,
2007 [41]
12 mat-moDC PSA-1, PSA-2, PSA-3 peptide IFN-gamma s.c. n.d. 10/12 1/12 PR, 1/12
MR,
4/12 SD
Kantoff,
2010 [42]
341 density
enriched
PA2024
1 protein i.v. 100/151 46/63 n.d.
Mu,
2005 [43]
19 mat-moDC cell lines DU145,
LNCaP, PC-3
mRNA i.d. or i.n. n.d. 13/19 11/19 SD
Murphy,
2000 [44]
28 imm-moDC PSM-P1 + PSM-P2
(+ KLH)
peptide i.v. n.d. n.d. 1/28 CR, 4/28
PR,
1/28 SD
Pandha, 2004 [34] 11 imm-moDC cell lines LNCaP,
DU145
cell lysate KLH i.d. i.d. or i.n. n.d. 11/11 4/11 SD
Perambakam,
2006 [45]
14 imm-moDC PSA (+ Flu-M1) peptide i.v. n.d. 5/14 n.d.
Small,
2000 [46]
31 density
enriched
PA2024
(+ KLH in 5 patients)
protein i.v. 16/31 31/31 3/31 PR,
28/31 SD**
Small,
2006 [33]
82 density
enriched
PA2024
1 protein i.v. n.d. n.d. n.d.
Su, 2005 [47] 20 mat-moDC hTERT or LAMPhTERT mRNA i.d. n.d. 17/18 n.d.
Thomas-Kaskel,
2006 [48]
12 mat-moDC PSCA, PSA
(+ HIV-gag)
peptide s.c. n.d. 5/12 6/12 SD
Waeckerle-Men,
2006 [49]
6 mat-moDC PSCA, PAP,
PSMA, PSA
peptide DC + FluM i.d. n.d. 3/4 0/3
RCC
Reference Patients DC
Antigen
(+ helper antigen)
Antigen
processing Adjuvant Route
Humoral
immune
response*
Cellular
immune
response*
Clinical
response
+
Berntsen,
2008 [50]
27 mat-moDC survivin, telomerase
(+ PADRE) or cell
lines A-498, Caki-1,
Caki-2 (+ KLH)
peptide or
tumor lysate
IL2 i.n. or i.d. n.d. 6/19 13/27 SD
Bleumer,
2007 [51]
8 mat-moDC CA9p254 +
CA9p249 (+ KLH)
peptide i.d. 0/6 6/6 0/6
Danull,
2005 [52]
10 mat-moDC auologous
tumor cells
total RNA DAB389IL-2 in
6 patients
(Treg depletion)
i.d. n.d. 9/10 n.d.
Gitlitz,
2003 [53]
12 imm-moDC autologous
tumor cells
tumor lysate i.d. n.d. 0/12 1/12 PR,
3/12 SD
Ho ¨ltl,
2002 [54]
35 mat-moDC autologous tumor
cells or cell line
A-498 (+ KLH)
tumor lysate i.v. or i.d. n.d. 5/6 2/35 CR, 1/35 PR,
7/35 SD
Kim,
2007 [55]
9 mat-moDC autologous tumor
cells (+ KLH)
tumor lysate s.c. n.d. 9/9 1/9 PR,
5/9 SD
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9/12).
Information about purity of DC vaccine was available only in
10 studies, (prostate cancer: 8/17, RCC: 2/12). Purity above 80%
proposed by Figdor and co-workers was indicated only in four
trials (prostate cancer: 3/17 and RCC: 1/12) [35,41,49,55].
Comparing RCC with prostate cancer revealed that information on
DC phenotype was slightly more detailed in RCC trials, whereas
the information on DC purity was better in prostate cancer trials.
Treatment related toxicity
DC vaccination was safe in both entities: only mild side effects
were described. Most adverse effects were local reactions at the
injection site, fever and flu-like symptoms. Less common were
myalgias, fatigue, bone or articular pains. Few toxicities were
detected above grade 2 or were linked to additional cytokine
therapy (e.g. [58]). A detailed overview is provided in Table S3.
Immune response assessment
The cellular immune response was determined in all studies
except for two [40,44]. At least one of the functional tests proposed
by Figdor – ELISPOT, cytotoxicity, or cytokine production after
antigen-specific stimulation [62] – was performed in the majority
of the studies (prostate cancer 10/17; RCC trials 10/12). Humoral
immune response using antigen-specific ELISA was reported in 6
of 17 prostate cancer and in 2 of 12 RCC trials.
Analysis of study data level (Table 1) revealed that DC
vaccination led to an antigen-specific cellular immune response
in 77% of patients with prostate cancer (196/256 patients tested) and
in 61% of patients with RCC (63/104 patients tested) (Fig. 2A). A
specific humoral immune response was detected in 55% of prostate
cancer patients (137/251 patients tested), whereas no humoral
response was observed in the few RCC patients tested (0/18
patients tested). Complete information about immune assessment
is summarized in Table S4.
Clinical response
Lackofradiologicallymeasurablediseaseis a frequentproblem in
prostatecancertrials.TheProstate-SpecificAntigenWorkingGroupof
the NCI has therefore incorporated PSA levels into remission
criteriaformetastaticdisease [63].Moststudiescombined both PSA
levels and radiological response [36–38,41,43,44,48]. In 12 of 17
trials ‘progressive disease’ as prerequisite before study entry was
explicitly required, whereas in the other 5 trials the study entry was
not limited, it was allowed for all patients with metastatic or
hormone refractory disease (Table S1). Six trials could not be
assessed for clinical response since: 1) clinical response was not
reported [45]; 2) only reports on PSA doubling times [39]; 3)
median time to progression (TTP) [33,40,42]; or 4) median PSA
courses of vaccination groups [47] were documented.
In RCC trials response criteria were in accordance to RECIST or
WHO criteria; however, these were explicitly mentioned only in 5
trials [16,55,56,58,61]. Eight studies only included patients with
documented progressive or new metastatic disease before nephrec-
tomy, in one study 85% of the patients had progressive disease, and in
three studies enrollment was allowed to all patients with metastatic
disease. In one trial clinical response was not reported [52]. Table S1
contains information about the trials clinical response evaluation.
Table 1. Cont.
RCC
Reference Patients DC
Antigen
(+ helper antigen)
Antigen
processing Adjuvant Route
Humoral
immune
response*
Cellular
immune
response*
Clinical
response
+
Ma ¨rten,
2002 [56]
15 mat-moDC autologous
tumor cells
#
(+ KLH in 2 patients)
tumor lysate s.c. or i.n. n.d. 2/9 1/15 PR, 7/15 SD
(2 patients with
SD received only
KLH pulsed DC)
Oosterwijk-
Wakka,
2002 [57]
12 imm-moDC autologous
tumor cells
(+ KLH in 6 patients)
tumor lysate IL2 i.d. 0/12 0/12 8/12 SD
Schwaab,
2009 [58]
18 mat-moDC autologous
tumor cells
tumor lysate IL2, IFN-a 2a i.n. increase of
anti-RCC IgM
increase of
RCC specific
CD8+IFNg
+Tcells
3/18 CR, 6/18 PR,
6/18 SD
Su,
2003 [59]
10 imm-moDC autologous
tumor cells
total RNA i.v. + i.d. n.d. 6/7 1/2 SD
Wei,
2007 [60]
10 mat-moDC autologous
tumor cells
cell fusion IL2 s.c. n.d. 9/9 1/10 PR,
3/10 SD
Wierecky,
2006 [61]
20 mat-moDC MUC-1
(+ PADRE)
peptide IL2 s.c. n.d. 11/18 1/20 CR, 2/20 PR,
2/20 MR, 5/20SD
Abbreviations: mat-moDC, mature monocyte derived dendritic cell; imm-moDC, immature monocyte derived dendritic cell; id, intradermal; in, intranodal; il,
intralymphatic; sc, subcutaneous; iv, intraveneous; CR, complete response; PR, partial response; MR, mixed response; SD, stable disease; PD, progressive disease; n.d., not
done.
*tumor antigen specific immune responses; details on all conducted tests are given in Table S4.
+for prostate cancer trials in which PSA courses were used for response criteria they are displayed if they were combined with radiological criteria; clinical responses are
indicated in relation to evaluable patients – additional clinical response information and trials response criteria are given in Table S1.
1PA2024 = huPAP/GM-CSF fusion protein.
#2 patients received unpulsed and another 2 patients only KLH pulsed DC.
**at least $8 weeks from registration.
{only results of the trial D9902A displayed; the publication also reported on an integrated analysis including the results of the trial D9901 [33].
doi:10.1371/journal.pone.0018801.t001
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cancer patients. 7.7% of the patients had an objective response
(CR+PR+MR). Additionally, 83 SD were observed representing a
clinical benefit rate (CBR) of 54% (97/181) (Fig. 2B). On the other
hand, in a total of 166 RCC patients investigated, objective
response rate was 12.7%. SD was found in 58 patients, resulting in
a CBR of 48% (79/166) (Fig. 2B; Table S1).
Meta-analysis
Individual data was available from 231 prostate cancer and 172
RCC patients (Table S5). Different variables were tested for their
influence on CBR in which stable diseases (SD) were included.
Separated stratified analyses for the influence only on CR+PR
were not possible due to their low number. Influence of the
following variables on CBR was assessed by conditional logistic
regression grouped by study: 1) cellular immune response, 2) total
DC dose, 3) humoral immune response, 4) age, and 5) gender of
RCC patients (Table 2). Additionally, the continuous variable DC
logdose was assessed. DC subtype and route of vaccination were
constant within most of the trials and therefore tested by means of
unstratified chi-square tests (Table 3).
The most relevant finding is that the cellular immune response
was found to have a significant influence on CBR, both in prostate
cancer (OR 10.6, 95% CI 2.5–44.1) and in RCC (OR 8.4, 95% CI
1.3–53.0) (Fig. 3).
For assessment of the influence of total DC dose, the median
between the trials served as threshold. Strikingly, a significant OR
was identified for higher DC doses both in prostate cancer and RCC
trials (prostate cancer: OR 4.8, 95% CI 1.2–18.9; RCC: OR 7.0, 95%
CI 1.9–25.0). To visualize stratified analyses by Forest plots for the
influence on clinical outcome of cellular immune response and
total DC dose, additional classical Mantel-Haenszel analyses were
conducted. Although compared to conditional logistic regression
fewer studies and lower patient numbers could be included in
these analyses, similar results, which were statistically significant,
were obtained (Figure S1).
To further study an association between increasing total DC
dose and clinical benefit, the non-dichotomised logarithmic total
DC dose (logdose) was assessed by conditional logistic regression.
Interestingly, for prostate cancer no continuous effect of increasing
DC dose could be observed (OR 1.3, 95% CI 0.6–2.9), but there
was a statistical significant effect in RCC trials (OR 4.4; 95% CI
2.3–8.5).
Specific humoral immune responses were determined only in 12
RCC patients. Thus, the analysis was not feasible for RCC.I n
prostate cancer patients no statistically significant association of
humoral response and CBR was detected (OR 0.8, 95% CI 0.1–
4.5). There was no significant association between the variables
age in both tumor entities and gender in RCC and CBR.
Chi-square tests across the studies revealed a significant positive
influence of DC maturation status on the CBR in prostate cancer
patients (mat-moDC vs. imm-moDC, OR 2.8, 95% CI 1.4–6.9).
Interestingly, vaccination routes with access to draining lymph
nodes (i.d., i.n., i.l., s.c) were found to result in better clinical
response rates in comparison to intravenous (i.v.) injections in both
tumor entities. Nevertheless, the OR was statistically significant
only in prostate cancer patients (OR 3.2, 95% CI 1.1–9.0). Strikingly,
comparing monocyte-derived DC with density-enriched DC in
prostate cancer trials revealed an advantage for density enriched DC
over moDC (OR 0.2, 95% CI 0.1–0.4). Even if the comparison
was restricted to mat-moDC, the analysis led to the same finding
(OR 0.3, 95% CI 0.1–0.7).
To further investigate the influence of DC subtype on CBR,
additional conditional logistic regression tests were performed
analyzing the variable DC logdose within the subgroups of patients
treated with either mature or immature moDC. In prostate cancer,
for both subgroups, this analysis did not change the statistically not
significant result described above. In contrast, in RCC, an influence
of the increasing DC dose was found only in the group of patients
treated with mat-moDC (OR 4.3, 95% CI 2.09–7.79) but not in
the group of patients treated with imm-moDC.
Discussion
A growing body of knowledge about tumor immunosurveillance
– and loss thereof – has contributed to the refinement of anti-
tumor immunotherapy [64]. Yet, despite high expectations in DC-
based vaccination trials, thus far clinical responses have been
disappointing [20,65,66]. Lack of efficacy can be explained by
well-defined tumor escape mechanisms [67–69], which are
currently being addressed by combining DC vaccination with
other approaches, such as CTLA4 [70] or CD25 blockade [52].
However it is also due to the design of clinical trials conducted so
Figure 2. Immune and clinical responses in prostate and renal
cell cancer (RCC) patients. (A) Induction of tumor antigen specific
cellular or humoral immune responses. An immune response was
considered positive when at least one of the conducted assays was
positive. (B) Analysis of objective response (black columns) and clinical
benefit rate (CBR; grey columns). CR, complete response; PR, partial
response; MR, mixed response; SD, stable disease.
doi:10.1371/journal.pone.0018801.g002
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end points safety or feasibility. The objective of this systematic
review and meta-analysis was to determine: first, whether an
association between immune and clinical response could be
detected; and second, which factors were associated with better
clinical outcome.
Interestingly, the total objective clinical response rates (7.7% for
prostate cancer and 12.7% for RCC) were quite similar compared
to DC-based vaccination trials in other tumor entities [20,65,71].
When including SD the clinical benefit rate (CBR) was 54% for
prostate cancer and 48% for RCC patients, which is consistent
with previous reports [14,16].
Results of meta-analysis of non-randomized phase I/II trials have
to be interpreted with caution. For example, the variables doseor DC
subtype represent potential confounders to each other. Moreover,
definitions of clinical endpoints and immune monitoring are not
always consistent among the trials (Tables S1 and S4). Nevertheless,
for the key variables (cellular immune response and dose) we could
perform conditional logistic regression grouped by study, thus
adjusting varying vaccination protocols or response criteria.
Table 2. Meta-analysis of influence on clinical benefit rate - conditional logistic regression grouped by study.
Prostate cancer
Variable Number of patients
$ OR 95% CI
p-value
(2-sided)
Cellular immune response 83 10.567 2.533–44.082 0.001*
Humoral immune response 21 0.760 0.128–4.522 0.763
Median dose ($86.4 vs. ,86.4610
6) 123 4.767 1.204–18.883 0.026*
Age ($65 vs. ,65) 43 2.620 0.657–10.438 0.172
Logdose 123 1.304 0.579–2.939 0.522
RCC
Variable Number of patients
$ OR 95% CI
p-value
(2-sided)
Cellular immune response 75 8.422 1.339–52.966 0.023*
Humoral immune response 12 n.a.
Median dose ($38.7 vs. ,38.7610
6) 148 6.973 1.948–24.967 0.003*
Age ($65 vs. ,65) 125 1.938 0.718–5.230 0.192
Gender (m vs. f) 105 1.134 0.450–2.857 0.790
Logdose 148 4.378 2.265–8.461 0.00*
Abbreviations: OR, odds ratio; CI, confidence interval, n.a., not applicable; m, male; f, female.
1Analyses restricted to number of patients with available data for the variables listed.
*significant.
doi:10.1371/journal.pone.0018801.t002
Table 3. Meta-analysis of influence on clinical benefit rate – chi-square analysis of pooled individual data across studies.
Prostate cancer
Variable
Number of
patients
$ OR 95% CI
p-value
(2-sided)
DC type (mat-moDC vs. imm-moDC)** 92 2.800 1.141–6.871 0.023*
DC type (moDC vs. density enriched DC) 157 0.202 0.099–0.411 0.000*
DC type (mat-moDC vs. density enriched DC) 119 0,300 0.137–0.658 0.002*
Application (id/in/il/sc vs. iv)** 84 3.150 1.107–8.963 0.028*
RCC
Variable
Number of
patients
$ OR 95% CI
p-value
(2-sided)
DC type (mat-moDC vs. imm-moDC) 154 1.0 0.430–2.324 1.0
Application (id/in/il/sc vs. iv) 152 2.188 0.776–6.107 0.132
Abbreviations: OR, odds ratio; CI, confidence interval; mat-moDC, mature monocyte derived dendritic cell; imm-moDC, immature monocyte derived dendritic cell; id,
intradermal; in, intranodal; il, intralymphatic; sc, subcutaneous; iv, intraveneous.
1Analyses restricted to number of patients with available data for the variables listed.
**without density-grade enriched DC.
*significant.
doi:10.1371/journal.pone.0018801.t003
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had to focus on CBR (CR+PR+MR+SD). However, this clinical
endpoint also addresses fundamental aspects of oncology: There is
an increasing debate on ideal clinical response criteria in active
immunotherapy approaches [72]. Thus far, most trials using DC-
vaccines have been conducted in the palliative setting of metastatic
or locally advanced disease. For these patients reducing symptoms
and prolonging survival time with acceptable side effects are the
primary clinical treatment objectives. Thus, overall survival (OS)
and time to progression (TTP) would be the ideal endpoints in this
situation. This identical challenge has been identified for so called
‘targeted drugs’ [73]. A significant prolongation of median OS was
first found in a randomized DC-based trial using density-enriched
DC conducted in metastatic prostate cancer [33], which is
included in this meta-analysis. It has recently been confirmed by
another phase III trial [42] and has led to the FDA approval of
Sipuleucel-T in hormone-refractory prostate cancer. When the
endpoints OS or TTP are not available, terms of disease
stabilization or clinical benefit rate might help evaluation of
therapeutic success [20,74]. However, as shown in our analysis the
differences in SD definitions remain problematic (Table S1).
Additionally, in nearly one third of the trials included in this study,
patients without documented progressive disease at study entry
were included. Thus, using CBR as a clinical endpoint will need
concise and consistent definitions of SD.
Despite the aforementioned limitations this meta-analysis
provides new insights into the field of cancer vaccination. First,
we found an association between specific cellular immune response
and clinical outcome, both in prostate cancer and RCC. Thus far,
this has been reported only within single trials in prostate cancer
[22,37,43,46,48] and RCC [61]. Importantly, this association
provides a proof of concept for DC-based vaccines. As analyzed in
detail, RCC and prostate cancer trials mostly differ in the chosen
clinical response criteria and vaccine strategies. For the latter this
was particularly observed in the preferred route of vaccination,
DC subtype, and different strategies for antigen delivery. Thus, the
observed link between induction of cellular immune response and
clinical benefit identified by stratified analyses is of great
importance due to the fact that is was identified independent of
the chosen vaccination strategy and it was, independently of each
other, found in both tumor entities.
The second finding relates to the dose of DC. We found a
positive influence of higher DC doses on CBR in both tumor
entities. The need of a sufficient amount of vaccinated DC to
enable activation of effector cells has already been suggested not
only in murine models [75], but also in clinical trials [76]. For
prostate cancer, Small described an association between DC dose
and TTP but failed to show statistical significance [46].
Interestingly, in prostate cancer a positive influence was not found
for continuous increasing doses. It seems that a high threshold
exists, which has to be exceeded in order to achieve a better
clinical response. In RCC also continuous increasing doses had a
positive influence on CBR. This difference found between the
tumor entities is difficult to interpret, but might be explained by
different dose distributions. In addition, it is relevant that in RCC
an influence of the increasing DC dose was only found in the
group of patients treated with mat-moDC, but not in the group of
patients treated with imm-moDC. This finding is of great interest
because it further underlines the importance of maturation status
as discussed below.
Specific humoral immune response was shown to have no
influence on CBR in prostate cancer. However, the number of
patients included in this stratified analysis was very low (Table 2).
Nevertheless, a chi-square test across the studies that allowed
inclusion of a higher number of patients (63) also failed to show a
significant association between humoral response and CBR (data
not shown).
Our analysis revealed that in prostate cancer patients
vaccination of mat- moDC was associated with a higher CBR
than vaccination with imm-moDC. For this analysis only
monocyte-derived DC were included as density-enriched DC
might have a different biology and few information on their
maturation status exist. It has been suggested that imm-moDC
bear the risk of inducing tolerance [67,77–79]. Indeed, Dhodapkar
and colleagues observed tolerizing effects of immature DC to
influenza matrix peptide in healthy individuals [80]. In melanoma
patients it has been demonstrated that maturation status affects not
only lymph-node homing [81], but also the induction of T-cell and
thus clinical responses [82,83]. However, no statistically significant
association of maturation status and clinical response has been
reported so far. Our finding adds weight to experimental evidence
of a tolerizing effect of imm-moDC. This observation could
however not be reproduced in RCC – likely due to an
inhomogeneous distribution of mat-moDC and imm-moDC
within the RCC trials.
Interestingly, comparing the influence on clinical outcome of
density-enriched DC with that of monocyte-derived DC in
prostate cancer revealed an advantage of density-enriched DC
over moDC, even if the comparison was restricted to mat-moDC.
This finding might further underscore the FDA approval of the
cellular therapeutic Sipuleucel-T [42]. Nevertheless, the limita-
tions of pooled chi-square analyses have to be kept in mind
especially for this comparison: using this method there is no
adjusting for potential systematic differences between the trials
using either DC type. For instance, in trials using density-enriched
DC, total DC dose was considerably higher than in trials using
Figure 3. Meta-analysis of the odds ratio (OR) of cellular immune response and clinical benefit rate. Conditional logistic regression
grouped by study using individual patient data revealed a statistically significant association between clinical benefit rate and induction of tumor
antigen specific cellular immune response for prostate cancer and renal cell cancer (RCC) patients. Horizontal lines denote 95% confidence intervals.
doi:10.1371/journal.pone.0018801.g003
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allow reliable conclusions about the superiority of either DC type.
The optimal route of vaccination is still subject to debate. DC
enter lymph nodes in afferent lymph vessels [84,85]. Mature DC
lack CD62L, a homing receptor necessary to enter lymph nodes
across high endothelial venules from the blood [84,86]. For these
reasons a route of vaccination allowing access to draining lymph
nodes (i.d., i.l., s.c., i.n) should be superior to an intravenous route.
Indeed, murine studies have established that intravenously injected
DC accumulate in the spleen and non-lymphoid tissues, but not in
the lymph nodes [87]. Our analysis revealed a positive influence
on CBR of a non-intravenous route (i.d., i.l., s.c., i.n) compared
with an intravenous route for moDC in both cancers, reaching
statistical significance only in prostate cancer. This finding
confirms observations in single trials that have compared different
routes [88]. The statistically not significant result for RCC might
be explained by the inhomogeneous distribution of intravenous
and non-intravenous routes in RCC trials.
This systematic review indicates that vaccine quality controls
clearly need improvement. Notably, only 10 out of 29 trials
reported the DC purity, and of these, only in four trials purity was
above 80% as propounded by Figdor [62]. Moreover, five clinical
trials reported no information about DC phenotype at all. One of
the prerequisites for future randomized clinical trials using DC
should be a definitive consensus about the vaccine quality controls.
Information about toxicity was provided in most of the trials and
our analysis further confirms that safety is no general issue in DC-
based immunotherapy anymore.
Taken together, our meta-analysis demonstrated an association
between specific cellular immune response and clinical benefit,
both in prostate cancer and RCC trials, thus implying a proof of
concept for DC vaccination. Moreover, this study provides
evidence for previous assumptions: Relevance of dose, mature
phenotype, and lymph-node access. However, the systematic
review also revealed a strong heterogeneity regarding DC purity
and dose, DC subtype, antigen delivery, route of vaccination, and
quality controls. Therefore, we conclude that DC-based immu-
notherapy clearly warrants further investigation in phase III
randomized trials. It is essential that future trials fulfill quality
criteria, e.g. as postulated by Figdor [62] and others [9,72]. It is
important not only to standardize the vaccine itself, but also the
immune monitoring and the criteria to assess clinical responses
[89]. Only if DC are generated and validated like a drug, can they
finally be made available to cancer patients as a standard option.
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